|Trade names||Vyxeos, Vyxeos liposomal|
|Main uses||Acute myeloid leukemia (AML)|
|Side effects||Bleeding, low neutrophils, rash, swelling, nausea, diarrhea, tiredness, cough, arrhythmias, sepsis|
Daunorubicin/cytarabine is a combination medicine used to treat acute myeloid leukemia (AML). Specifically it is used for therapy related disease (t-AML) or AML with myelodysplasia-related changes (AML-MRC). It is given by a central venous line. The combination differs from the individual components.
Common side effects include bleeding, low neutrophils, rash, swelling, nausea, diarrhea, tiredness, cough, arrhythmias, and sepsis. Other side effects may include heart toxicity, anaphylaxis, and tissue necrosis. Use in pregnancy may harm the baby. Daunorubicin is an anthracycline topoisomerase inhibitor while cytarabine is a nucleoside metabolic inhibitor. These are contained with liposomes.
The combination was approved for medical use in the United States in 2017 and Europe in 2018. In the United Kingdom a vial of 44 mg daunorubicin/100 mg cytarabine costs the NHS about £4,600 as of 2021. This amount in the United States costs about 9,300 USD.
- "DailyMed - VYXEOS (- daunorubicin and cytarabine liposome injection, powder, lyophilized, for suspension". dailymed.nlm.nih.gov. Archived from the original on 29 March 2021. Retrieved 21 December 2021.
- "DAUNOrubicin and Cytarabine Monograph for Professionals". Drugs.com. Archived from the original on 5 March 2021. Retrieved 21 December 2021.
- "Vyxeos liposomal (previously known as Vyxeos)". Archived from the original on 6 May 2021. Retrieved 21 December 2021.
- BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 945. ISBN 978-0857114105.
- "Vyxeos Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 18 April 2021. Retrieved 21 December 2021.